Adsett Roger sold $242K of INSM

Insmed (INSM) announced the FDA granted priority review for its ARIKAYCE lung drug, setting a January 2027 decision date. The application seeks full approval for broader use in treating MAC lung disease. Clinical trial results showed significant improvements in respiratory symptoms and bacterial conversion rates. Success could expand the patient pool and increase revenue, but regulatory, tolerability, and commercialization risks remain.

FDA granted Priority Review to Insmed's sNDA for Arikayce to treat MAC lung disease. Sotatercept's label updated with HYPERION trial data. Celldex's barzolvolimab met endpoints in CSU trials. Eli Lilly's Onswik approved for type 2 diabetes. Gazyva approved for idiopathic nephrotic syndrome.

Insmed (INSM) announced FDA Priority Review for ARIKAYCE in MAC lung disease, based on positive Phase 3b ENCORE trial results. The company projects $4.1B revenue and $1.0B earnings by 2029, with ARIKAYCE potentially expanding its rare disease portfolio. Analysts' views vary, with some forecasting slower uptake. The FDA decision is expected by January 28, 2027.

Insmed (INSM) announced the FDA accepted its filing for Arikayce's label expansion to treat newly diagnosed MAC lung disease, with a decision expected by Jan. 28, 2027. The filing is supported by positive phase IIIb ENCORE study results. Arikayce sales grew 7% YoY to $214.4M in H1 2026, with full-year sales projected at $450M-$470M. The expansion could significantly increase Arikayce's market potential, according to the company.

Insmed stock rose 2.0% in pre-market trading after the FDA accepted and granted Priority Review to its sNDA for ARIKAYCE, targeting a decision by January 28, 2027. The application seeks full approval for the drug, backed by Phase 3b ENCORE study results. Full approval would expand ARIKAYCE's use to newly diagnosed patients and those with recurrent infections. Insmed also plans to engage Japan's pharmaceutical regulator in Q4 2026 for potential label expansion.

Insmed Inc. (NASDAQ:INSM) shares rose 2% premarket after the FDA granted priority review to its sNDA for Arikayce, targeting MAC lung disease. The FDA set a review deadline of January 28, 2027. Arikayce, approved in 2018, could see expanded use if the application succeeds. The sNDA is backed by Phase 3b ENCORE study results showing significant improvements in respiratory symptoms and culture conversion.